Back-to-Back 79 Upper Circuits, 1:1 Bonus Issue and 1:2 Share Split Proposal: Sampre Nutritions Approves Rs 355 Crore FCCB

Sampre Nutritions Limited, a leading confectionery manufacturer, has received board approval to issue foreign currency convertible bonds (FCCBs) totaling USD 4 crore, equivalent to Rs 355.06 crore. The company plans to issue 400 FCCBs, each valued at USD 1,00,000. The funds raised through this initiative will be used to expand Sampre Nutritions’ global footprint, targeting emerging markets in Egypt and Liberia (Monrovia), aiming to diversify revenue streams and strengthen its presence in the international FMCG sector. ARIES CAPITAL LIMITED has been appointed as the Lead Arranger for listing and underwriting the FCCB issue. The bonds will be available for subscription on the AFRINEX EXCHANGE MAURITIUS from October 10, 2025, to October 15, 2025.

In addition, Sampre Nutritions’ board approved a bonus issue and stock split in its September 19, 2025 meeting. Each equity share of face value Rs 10 will be split into two shares of Rs 5 each. Alongside this, a bonus issue in the ratio of 1:1 will be implemented, issuing one bonus equity share of Rs 5 for every fully paid equity share of Rs 5. The bonus issue will be funded with Rs 21.55 crore from the company’s securities premium account, which holds free reserves of Rs 59.86 crore as per audited financials for the year ending March 31, 2025. The bonus shares are expected to be credited on or before December 19, 2025.

Sampre Nutritions has also strengthened promoter holdings through the conversion of 550,000 warrants into equity shares. Of these, 500,000 were allotted to Mr. Brahma Gurbani and 50,000 to Mr. Vishal Ratan Gurbani. The conversion was done for cash, realising 75 per cent of the exercise price at Rs 45.375 per warrant from the full price of Rs 60.50. This follows shareholder approval on December 8, 2023, and BSE in-principle approval on October 29, 2024.

The company has entered into new manufacturing agreements to drive revenue growth. A contract with Tolaram Wellness Ltd., Nigeria, signed on August 16, 2025, will generate approximately Rs 10 crore annually, totalling around Rs 30 crore over three years. Payment terms include 50 per cent advance and the balance on dispatch, with transportation costs borne by Tolaram Wellness. Another three-year agreement with Rama Exports, signed on August 19, 2025, is expected to generate Rs 15 crore over its tenure, strengthening the company’s operational depth in nutraceutical and food production.

Sampre Nutritions reported strong financial performance for Q1FY26 ending June 30, 2025. Revenue from operations reached Rs 10.87 crore, marking a 141 per cent year-on-year increase from Rs 4.51 crore in Q1FY25. Net profit for the quarter stood at Rs 70.76 lakh, up 615 per cent from Rs 9.89 lakh in Q1FY25.

The company is planning further capital-raising initiatives through preferential issues, qualified institutional placements (QIP), and public or private offerings. A board meeting will be scheduled to seek shareholder approval for these plans, aimed at supporting ongoing expansion and strengthening financial structure. Sampre Nutritions has also been recognised with the Certificate of Recognition under the India 5000 Best MSME Awards 2024 for excellence in quality, customer satisfaction, and societal impact.

Sampre Nutritions’ share price has been on a remarkable run, hitting 79 back-to-back Upper Circuits. On Tuesday, the stock locked in the 2 per cent upper circuit at Rs 131.20 per share, delivering returns of over 400 per cent during this streak.

Disclaimer: The article is for informational purposes only and not investment advice.